← ANALYST RATINGS · TIPRANKS
Opko Health (OPK): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $3.08, the highest $4.00, the lowest $2.25. The average is +101.5% from the last price of $1.53.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Michael Petusky★★★★★★★★★★#4246 · hits 45% · avg +2.3% | Barrington | $2.25 | Buy | +47.1% | Upgrade | 16.10.26on TipRanks 07:40 | −3.9% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $3.00 → $4.00+33.3% | Buy | +161.4% | Reiterated | 16.10.26on TipRanks 07:35 | −3.9% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $3.00 | Buy | +96.1% | Reiterated | 15.10.26on TipRanks 12:08 | +17.2%next day −3.9% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $1.50 | Hold | −2.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 | Hold | −2.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $1.50 | Hold | −2.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $1.50 | Hold | −2.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $1.50 | Hold | −2.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 | Hold | −2.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| Unknown Analyst | Ladenburg Thalmann & Co. | $3.00 | Buy | +96.1% | Reiterated | 27.02.26on TipRanks 15:12 | +0.5%next day +3.3% · 5 days +0.3% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | — | Hold | — | Initiated | 20.11.25on TipRanks 04:50 | +0.8%next day +0.5% · 5 days −0.1% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $1.60 | Hold | +4.6% | Downgrade | 31.10.25on TipRanks Oct 30 19:35 | −7.2%next day +2.8% · 5 days +0.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Opko Health
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $3.00 at a price of $1.61 (+86.3%); now: $3.08 at $1.53 (+101.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 4 | 3 | 3 |
| Buy | 1 | 0 | 0 | 0 | 0 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.07 (from $-0.08 to $-0.05). Last quarter: $-0.01.
Sales
Next quarter’s sales estimate — $137M (from $135M to $138M). Last quarter: $164M.
Best top-analyst consensus in the sector · Healthcare
About Opko Health
- CEO: Phillip Frost
- Employees: 2,275
- 4400 Biscayne Boulevard, Miami, FL, 33137, US
- www.opko.com
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. T
Data from the stock’s TipRanks forecast page, read 35 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗